New Research Brief Series Launched by IVI to Share Learnings from the Open-Source Value Project

Guest post by Mark Linthicum, Director of Scientific Communications at The Innovation and Value Initiative To get to Value Assessment 2.0, a concerted effort across fields of expertise is needed to improve methods and establish practical approaches that make sense in real-world decision making. The Innovation and Value Initiative’s Open-Source Value Project aims to catalyze…

Are open-source approaches to value measurement the wave of the future?

My colleagues Jeroen Jansen, Devin Incerti along with Jeff Curtis think so. In JMCP they write: In the United States, there is an increased interest to understand the value of health technologies. Cost-effectiveness analysis is arguably the most appropriate framework to quantify value and to inform reimbursement decision making regarding medical interventions; however, a thorough…

IVI Webinars On New Open-Source Value Model

IVI will be hosting two webinars introducing our new open-source value model in non-small cell lung cancer. Devin Incerti and Jeroen Jansen will lead the webinar tomorrow. Modernizing Models for Value Assessment: A Detailed Discussion of the Open-Source IVI-NSCLC Model Date: February 27, 2019 at 2:30 PM EST / 11:30 AM PST Content: In-depth discussion…

Open-Source Decision Model for Value Assessment Rheumatoid Arthritis Treatments

In a recently published paper in PharmacoEconomics, I–along with co-authors Devin Incerti, Jeff Curtis, Darius Lakdawalla, and Jeroen Jansen–describe a recently developed open-source platform for measuring the value of treatments for rheumatoid arthritis. The model itself is here, but and the abstract from Incerti et al. (2019) is below: Objective The nature of model-based cost-effectiveness…

IVI-NSCLC Value Tool

Please see below some exciting news from the Innovation and Value Initiative (IVI) on the release of the IVI-NSCLC Value Tool. The press release is below. IVI is excited to publish our Open-Source Value Platform (OSVP) model focusing on epidermal growth factor receptor (EGFR) positive, non-squamous non-small cell lung cancer (NSCLC), and we invite public…

Innovation and Value Initiative in the news

The Innovation and Value Initiative (IVI) where I serve as the Director of Research was recently in the news with a Journal of Clinical Pathways interview with Executive Director Jennifer Bright and Director of Scientific Communications Mark Linthicum.  Some excerpts: Can you tell us about the Innovation and Value Initiative? Bright: We are working in three primary areas.…

The IVI-NSCLC model is coming

The Innovation and Value Initiative today announced that it is in the process of releasing a new model and value tool to evaluate treatments for for EGFR-positive non-small cell lung cancer (NSCLC).  More details on the model (named the IVI-NSCLC model) are available here, which includes a study protocol and model timeline. Oncology is an…